# LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease

> **NCT02365519** · PHASE2 · COMPLETED · sponsor: **Alcon, a Novartis Company** · enrollment: 514 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **BIOLOGICAL:** LME636 ophthalmic solution
- **BIOLOGICAL:** LME636 Vehicle

## Key facts

- **NCT ID:** NCT02365519
- **Lead sponsor:** Alcon, a Novartis Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-09
- **Primary completion:** 2015-10-16
- **Final completion:** 2015-10-16
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2018-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02365519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02365519, "LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02365519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*